If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Re: AIM Rule 26

20 Aug 2007 07:02

ReNeuron Group plc20 August 2007 AIM Rule 26 Guildford, UK, 20 August 2007: ReNeuron Group plc (LSE: RENE.L) is pleased toannounce that the information required by Rule 26 of the AIM Rules for Companies(Company Information Disclosure) is available on ReNeuron's website atwww.reneuron.com. Enquiries: ReNeuronMichael Hunt, Chief Executive Officer Tel: +44 (0) 1483 302560Dr John Sinden, Chief Scientific Officer Financial DynamicsDavid Yates Tel: +44 (0) 20 7831 3113Claire Rowell Collins Stewart Europe LimitedTim Mickley Tel : +44 (0)20 7523 8350 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Apr 20197:00 amRNSReNeuron to present at UK investor conference
4th Apr 20197:00 amRNSClinical update and conference presentation
28th Mar 20192:05 pmRNSSecond Price Monitoring Extn
28th Mar 20192:00 pmRNSPrice Monitoring Extension
18th Mar 201912:00 pmRNSAlliance for Regenerative Medicine presentation
18th Mar 20197:00 amRNSRetinal clinical trial progresses to next stage
12th Mar 20192:30 pmRNSNotification of Major Holdings
5th Mar 201912:56 pmRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
28th Feb 20197:00 amRNSBlock Listing Review and Total Voting Rights
20th Feb 20197:00 amRNSPositive preliminary data in US retinal trial
31st Jan 20197:00 amRNSNew exosome production scale-up data presented
24th Jan 20197:00 amRNSFirst patient treated in US stroke trial
4th Jan 20197:00 amRNSReNeuron signs exosome collaboration
14th Dec 20187:00 amRNSInterim Results
20th Nov 20182:00 pmRNSNotification of Interim Results
18th Oct 20187:00 amRNSReNeuron's lead cell line shows further potential
28th Sep 20182:16 pmRNSDirector/PDMR Interest in Shares and Share Options
27th Sep 20183:02 pmRNSDirectors Share Purchases
19th Sep 20184:40 pmRNSSecond Price Monitoring Extn
19th Sep 20184:35 pmRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSBusiness development update
12th Sep 201811:40 amRNSResult of AGM
12th Sep 20187:00 amRNSAGM Trading Update
31st Aug 20187:00 amRNSBlock Listing Review and TVR
31st Jul 20183:25 pmRNSPosting of Annual Report & Notice of AGM
17th Jul 20187:00 amRNSNotification of Major Holdings
16th Jul 20183:39 pmRNSNotification of Major Holdings
16th Jul 20187:00 amRNSNotification of Major Holdings
13th Jul 201811:50 amRNSNotification of Major Holdings
12th Jul 20187:00 amRNSPreliminary Results
11th Jul 20187:00 amRNSSigns retinal stem cell exclusivity agreement
4th Jul 20182:15 pmRNSNotification of Preliminary Results
17th May 20187:00 amRNSCapital Markets Event
4th May 20187:00 amRNSExosome data presented at ISCT conference
30th Apr 20187:00 amRNSCapital Markets Event and Webcast
19th Apr 20187:00 amRNSWins grant for retinal cell therapy development
10th Apr 20181:00 pmRNSAppointment of US-based Chief Medical Officer
26th Mar 20187:00 amRNSProduct Development Update
1st Mar 20187:00 amRNSBlock Listing Review and TVR
16th Feb 20187:00 amRNSBlock Listing Application
13th Feb 201810:00 amRNSPositive pre-clinical data in nerve injury
26th Jan 20187:00 amRNSPhase II stroke data presented at AHA conference
23rd Jan 201811:06 amRNSApproval of Share Capital Reorganisation
11th Jan 20187:00 amRNSFurther re Share Capital Reorganisation
5th Jan 20187:00 amRNSProposed Share Capital Reorganisation
14th Dec 20177:00 amRNSInterim results
14th Dec 20177:00 amRNSStroke clinical trial regulatory approval in US
8th Dec 20177:00 amRNSReNeuron opens US office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.